JP2017509624A - 心血管リスクを低減させる方法 - Google Patents

心血管リスクを低減させる方法 Download PDF

Info

Publication number
JP2017509624A
JP2017509624A JP2016556709A JP2016556709A JP2017509624A JP 2017509624 A JP2017509624 A JP 2017509624A JP 2016556709 A JP2016556709 A JP 2016556709A JP 2016556709 A JP2016556709 A JP 2016556709A JP 2017509624 A JP2017509624 A JP 2017509624A
Authority
JP
Japan
Prior art keywords
antibody
pcsk9
antigen
patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016556709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509624A5 (https=
Inventor
ロランス・ベサック
コリンヌ・アノトン
ロバート・シー・ポーディー
ウィリアム・ジェイ・サシーラ
グレゴリー・ジー・シュウォルツ
フィリップ・ガブリエル・シュテグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2017509624A publication Critical patent/JP2017509624A/ja
Publication of JP2017509624A5 publication Critical patent/JP2017509624A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016556709A 2014-03-17 2015-03-13 心血管リスクを低減させる方法 Pending JP2017509624A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US61/954,094 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US62/025,400 2014-07-16
US201462043182P 2014-08-28 2014-08-28
US62/043,182 2014-08-28
EP15305293 2015-02-26
EP15305293.1 2015-02-26
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020097344A Division JP2020143156A (ja) 2014-03-17 2020-06-04 心血管リスクを低減させる方法

Publications (2)

Publication Number Publication Date
JP2017509624A true JP2017509624A (ja) 2017-04-06
JP2017509624A5 JP2017509624A5 (https=) 2018-04-12

Family

ID=52648962

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016556709A Pending JP2017509624A (ja) 2014-03-17 2015-03-13 心血管リスクを低減させる方法
JP2022116854A Pending JP2022141868A (ja) 2014-03-17 2022-07-22 心血管リスクを低減させる方法
JP2024115429A Pending JP2024147744A (ja) 2014-03-17 2024-07-19 心血管リスクを低減させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022116854A Pending JP2022141868A (ja) 2014-03-17 2022-07-22 心血管リスクを低減させる方法
JP2024115429A Pending JP2024147744A (ja) 2014-03-17 2024-07-19 心血管リスクを低減させる方法

Country Status (14)

Country Link
US (2) US20150284473A1 (https=)
EP (2) EP4403213A3 (https=)
JP (3) JP2017509624A (https=)
KR (3) KR20250006995A (https=)
CN (3) CN106794244A (https=)
AU (3) AU2015231713B2 (https=)
CA (1) CA2942549A1 (https=)
EA (1) EA039310B1 (https=)
ES (1) ES2978990T3 (https=)
HU (1) HUE066839T2 (https=)
IL (1) IL304491A (https=)
MX (1) MX380767B (https=)
PL (1) PL3119810T3 (https=)
WO (1) WO2015142668A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515772A (ja) * 2018-03-06 2021-06-24 サノフィ・バイオテクノロジー 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US12606638B2 (en) 2013-11-12 2026-04-21 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
US12612466B2 (en) 2023-04-28 2026-04-28 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
RU2723018C2 (ru) * 2014-07-16 2020-06-08 Санофи Байотекнолоджи Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10329620B2 (en) * 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
CN112912071A (zh) * 2018-08-17 2021-06-04 阿玛林制药爱尔兰有限公司 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
JP7692411B2 (ja) * 2019-11-07 2025-06-13 メディミューン，エルエルシー 心血管疾患の治療用の内皮リパーゼ抗体
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
BR112022009587A2 (pt) * 2019-11-18 2022-08-02 Ad Pharmaceuticals Co Ltd Anticorpo anti-pcsk9 e uso do mesmo
MX2022012752A (es) * 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511913A (ja) * 2008-12-15 2012-05-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｃｓｋ９に対する高親和性ヒト抗体
WO2012154999A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PL3395836T3 (pl) * 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012511913A (ja) * 2008-12-15 2012-05-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｃｓｋ９に対する高親和性ヒト抗体
WO2012154999A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EPRESSPACK, JPN6018043429, October 2013 (2013-10-01), ISSN: 0004207089 *
EVAN A STEIN; GARY D SWERGOLD: "POTENTIAL OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 BASED THERAPEUTICS", CURRENT ATHEROSCLEROSIS REPORTS, vol. VOL:15, NR:3, JPN5017002439, 1 February 2013 (2013-02-01), US, pages 1 - 14, ISSN: 0004207090 *
MCKENNEY, J.M. ET AL., J AM COLL CARDIOL, vol. 59, no. 25, JPN6019018974, 2012, pages 2344 - 53, ISSN: 0004207091 *
REGENERON NEWSROOM, JPN6018043428, December 2013 (2013-12-01), ISSN: 0004207088 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083176B2 (en) 2011-01-28 2024-09-10 Sanofi Biotechnology Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
US12606638B2 (en) 2013-11-12 2026-04-21 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
JP2021515772A (ja) * 2018-03-06 2021-06-24 サノフィ・バイオテクノロジー 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用
JP7426940B2 (ja) 2018-03-06 2024-02-02 サノフィ・バイオテクノロジー 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用
JP2024028919A (ja) * 2018-03-06 2024-03-05 サノフィ・バイオテクノロジー 心血管リスクを低減するためのｐｃｓｋ９阻害剤の使用
US12612466B2 (en) 2023-04-28 2026-04-28 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-PCSK9 antibodies

Also Published As

Publication number Publication date
EP3119810A1 (en) 2017-01-25
MX2016011975A (es) 2016-12-05
CN114642661A (zh) 2022-06-21
HUE066839T2 (hu) 2024-09-28
US20220144969A1 (en) 2022-05-12
US20150284473A1 (en) 2015-10-08
KR20220157516A (ko) 2022-11-29
AU2024205254A1 (en) 2024-10-03
EP4403213A2 (en) 2024-07-24
AU2015231713B2 (en) 2020-11-19
JP2024147744A (ja) 2024-10-16
JP2022141868A (ja) 2022-09-29
KR20160132459A (ko) 2016-11-18
CA2942549A1 (en) 2015-09-24
ES2978990T3 (es) 2024-09-23
EA039310B1 (ru) 2022-01-12
KR20250006995A (ko) 2025-01-13
WO2015142668A1 (en) 2015-09-24
EA201691847A1 (ru) 2017-01-30
AU2015231713A1 (en) 2016-10-20
EP4403213A3 (en) 2024-10-23
AU2021201118A1 (en) 2021-03-11
CN114558129A (zh) 2022-05-31
MX380767B (es) 2025-03-12
EP3119810C0 (en) 2024-02-28
EP3119810B1 (en) 2024-02-28
PL3119810T3 (pl) 2024-07-15
CN106794244A (zh) 2017-05-31
IL304491A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
JP2022141868A (ja) 心血管リスクを低減させる方法
JP7467538B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
JP6994484B2 (ja) 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用
JP6912374B2 (ja) 高コレステロール血症を有する高心血管リスク患者を処置するための方法
CN107922507B (zh) 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
TW201536315A (zh) 治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症之方法
CN106029096A (zh) 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法
JP2019512472A (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
JP2020143156A (ja) 心血管リスクを低減させる方法
HK40114248A (en) Methods for reducing cardiovascular risk
JP7104108B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
HK1232890B (en) Methods for reducing cardiovascular risk
HK1232890A1 (en) Methods for reducing cardiovascular risk
HK1255470B (en) Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200204